论文部分内容阅读
目的观察吉非替尼单药治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法对16例化疗失败的晚期NSCLC患者给予吉非替尼口服250mg·d-1,至病情进展或出现不可耐受的不良反应。结果 16例晚期NSCLC患者中,无完全缓解者,部分缓解(PR)4例(25.0%),稳定(SD)6例(37.5%),临床获益率(PR+SD)为62.5%。临床获益率与性别、吸烟史及癌症分期无关。到随访截止日期,16例患者中,6例存活,10例死亡;中位肿瘤进展时间(TTP)为7个月,中位生存期(MST)为10个月。不良反应主要为Ⅰ～Ⅱ度皮疹和腹泻,对症处理后可缓解。结论吉非替尼有明显抗肿瘤作用,能明显提高晚期NSCLC患者的生活质量,改善临床症状,不良反应可以耐受。
Objective To observe the efficacy and side effects of gefitinib monotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Twenty-six patients with advanced NSCLC who had failed chemotherapy were given 250 mg · d-1 gefitinib orally, and the disease progressed or intolerable adverse reactions. Results Among the 16 patients with advanced NSCLC, there were 4 patients (25.0%) with partial remission (PR), 6 (37.5%) with stable (SD) and 62.5% with PR + SD. The clinical benefit rate was unrelated to gender, smoking history and cancer staging. By the deadline for follow-up, 6 of 16 patients survived and 10 died; median tumor progression time (TTP) was 7 months and median survival (MST) was 10 months. Adverse reactions mainly Ⅰ ~ Ⅱ rash and diarrhea, symptomatic treatment can be alleviated. Conclusion Gefitinib has obvious anti-tumor effects, can significantly improve the quality of life of patients with advanced NSCLC, improve clinical symptoms, adverse reactions can be tolerated.